Akari Therapeutics Expands ADC Pipeline with AKTX-102, a Novel ADC Targeting CEACAM5 Expressing Solid Tumors

Akari Therapeutics has filed a new patent application for its second ADC pipeline candidate, AKTX-102, targeting CEACAM5-expressing solid tumors. The ADC combines a novel CEACAM5-targeting antibody construct with Akari's proprietary PH1 spliceosome-modulating payload, aiming to deliver potent tumor cell killing while activating both innate and adaptive immune responses. The patent further expands Akari's intellectual property portfolio, covering payload biology, ADC architecture, and combination strategies.